Grant: Doctoral Research Award: Canada Graduate Scholarships
Université de Montréal
$120,000.00
Probing senescence in ovarian cancer treatment resistance: a story through time and space
FY 2024-25
Summary
Ovarian cancer poses a significant challenge for patients: while they respond well to treatment at first, the cancer usually comes back stronger, leading to poor survival. One way therapy affects cancer cells is by making them senescent, a state in which they stop dividing. In cancer, cells divide uncontrollably: senescence can be beneficial by slowing their progression. Surprisingly, senescence can also have opposite effects and promote cancer progression through other processes. A new treatment idea aims to force cancer cells into senescence to stop their division, then destroy them with specific drugs before they can cause harm.
However, a major challenge remains: senescent cells are very different from one another and can change over time or in different parts of the tumor. This makes it hard to target them all with one treatment, which could lead to resistance if some cells survive. We believe that finding a unique signature for each type of senescent cell in these different situations will reveal their weaknesses. This could then lead to better ways to target these different cells and prevent the cancer from becoming resistant.
To study these signatures, we use mouse models that closely mimic real ovarian cancer patients' tumors, letting us observe the treatment response without putting patients at risk. We also use advanced technologies to analyze each cell individually and understand how they differ from one another. Then, we'll look at these differences over time and in different parts of the tumor to create a full portrait of the senescent cells' responses.
By identifying these signatures, we hope to discover new drug targets and create treatments tailored to each patient, helping to avoid resistance and improve survival. This cutting-edge research not only promises a deeper understanding of ovarian cancer resistance, but also holds the potential to transform treatment approaches in other similarly resistant cancers.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
518434
Name
Montpetit Jade
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Probing senescence in ovarian cancer treatment resistance: a story through time and space
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Biomarker Discovery; Organoids; Ovarian Cancer; Patient-Derived Xenografts (Pdx); Personnalized Medecine; Preclinical Models; Rna Sequencing; Senescence; Spatio-Temporal Analysis; Treatment Resistance
Abstract
Ovarian cancer poses a significant challenge for patients: while they respond well to treatment at first, the cancer usually comes back stronger, leading to poor survival. One way therapy affects cancer cells is by making them senescent, a state in which they stop dividing. In cancer, cells divide uncontrollably: senescence can be beneficial by slowing their progression. Surprisingly, senescence can also have opposite effects and promote cancer progression through other processes. A new treatment idea aims to force cancer cells into senescence to stop their division, then destroy them with specific drugs before they can cause harm.
However, a major challenge remains: senescent cells are very different from one another and can change over time or in different parts of the tumor. This makes it hard to target them all with one treatment, which could lead to resistance if some cells survive. We believe that finding a unique signature for each type of senescent cell in these different situations will reveal their weaknesses. This could then lead to better ways to target these different cells and prevent the cancer from becoming resistant.
To study these signatures, we use mouse models that closely mimic real ovarian cancer patients' tumors, letting us observe the treatment response without putting patients at risk. We also use advanced technologies to analyze each cell individually and understand how they differ from one another. Then, we'll look at these differences over time and in different parts of the tumor to create a full portrait of the senescent cells' responses.
By identifying these signatures, we hope to discover new drug targets and create treatments tailored to each patient, helping to avoid resistance and improve survival. This cutting-edge research not only promises a deeper understanding of ovarian cancer resistance, but also holds the potential to transform treatment approaches in other similarly resistant cancers.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Montpetit, Jade
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~